Procedures
tumor, death, loose stools, diarrhea, toxicity, Cancer
DISEASE PROGRESSION, TUMOR, ADVERSE EVENT, ADVERSE EVENT, CANCER
In eligible patients, oral pyrotinib 400 mg and letrozole 2.5 mg were administered daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Prophylactic loperamide was not employed for preventing diarrhea. As soon as patients experienced grade 1 diarrhea, loperamide was administered at a dosage of 4 mg, followed by additional doses of 2 mg for every subsequent instance of loose stools, up to a maximum daily dose of 16 mg.Enhanced computed tomography or magnetic resonance imaging was performed every 8 weeks to assess tumor response until disease progression or death in accordance with RECIST v1.1. A confirmation should be made in the next assessment. Adverse events (AEs) reported during the study were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03.